MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_Personalized, Precision, Preemptive Medicines
Oncorus, Inc. (NASDAQ:ONCR)
Organization & Developments: Oncorus
Parents
Oncorus, Inc. (NASDAQ:ONCR)
Children
2021: Oncorus Inc.: Undervalued Cancer Viral Immunotherapy Opportunity
2022: Oncorus drops HSV solid tumor prospect, lays off 15% of workforce
2022: Oncorus has early stage trials ongoing including one for solid tumors and another for non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and melanoma based on viral tropism
2023: After layoffs leave Oncorus a 'shell' of a company, board liquidates the business
2023: Facing bankruptcy, RNA-focused Oncorus lays off 'substantially' all its staff
Oncorus, Inc. (NASDAQ: ONCR) is a viral immunotherapies company developing treatments for cancer patients
Jumps
Finance & Acquisitions: Oncorus
Key People: Oncorus